NEORIS to Share Insights on Disruptive Innovation at DES2018 | Digital Business World Congress
16.5.2018 18:11:00 EEST | Business Wire | Press release
NEORIS today announced it is one of the main sponsors of the DES2018 | Digital Business World Congress, the world’s largest international forum on digital transformation, which will celebrate its third edition in Madrid (IFEMA) May 22-24, 2018.
With the theme “Facing the Digital Avalanche,” the main goal of the #DES2018 (Digital Enterprise Show), is to offer solutions for different business areas, improving competitiveness and promoting digital transformation while ensuring speed and safety. Artificial Intelligence will be in the spotlight as the main trend during the show, as #DES2018 reunites top tech solutions that are driving the development of new business models such as IoT, Cloud, Cybersecurity, Big Data, Blockchain and Digital Marketing, among many others.
As part of its participation in #DES2018, NEORIS will share its views on the dawn of Artificial Intelligence and its implications on the present and future of business and humanity. In a special session titled “Real Intelligence: The True Challenges and Implications of AI”, Anthony DeLima, NEORIS’ CTO and Global Head of Digital Transformation, will explore the rapid evolution of Artificial Intelligence, how it’s transforming our lives and forcing us to question our own future.
“Artificial Intelligence holds the promise of new possibilities for businesses and the human species in general,” said DeLima. “Its capabilities are enabling organizations to dramatically reinvent themselves and ignite new and exciting interactions with customers and their industry. At the same time, the rapid advancements in AI –which are evolving much faster than we think– pose some critical ethical challenges.”
NEORIS knows firsthand how disruptive technologies are critical enablers to produce a digital transformation culture, based on its deep industry knowledge and experience helping customers achieve smarter interactions in the Healthcare, Financial Services, Manufacturing and Telecommunications industries around the globe.
NEORIS will present solutions for these industries, including demos that highlight different AI dimensions to accelerate business transformation in the evolving digital economy.
About NEORIS
NEORIS is a leading global consultancy that co-creates disruptive solutions for digitally aspiring companies to boost their connections with their customers, employees and stakeholders; ignited by creative teams with deep industry knowledge and technical expertise.
Headquartered in Miami, FL., NEORIS has a network of global delivery centers, design studios and operations in the U.S., Europe, Latin America, Africa, the Middle East and Asia.
More information is available at http://www.neoris.com, on Facebook or Twitter @NEORIS.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180516005948/en/
Contact information
NEORIS
US:
Paula Amador, 305-728-6044
paula.amador@neoris.com
or
Aileen
Abella, 305-310-6377
aileen@aileenabella.com
or
SPAIN:
Ax
Comunicación
Irene Herranz, Tel: + 34 915 612 962
iherranz@axcomunicacion.com
or
Manuel
Álvarez, Tel: + 34 607 558 751
malvarez@axcomunicacion.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 12:47:00 EEST | Press release
Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food products. Within this inspiring premise, Good Food Makers confirms itself as one of the main levers f
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 11:16:00 EEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom